β-Anomer exhibits significant antiviral activity against Yellow Fever Virus (YFV) and Influenza viruses A and B. In Syrian golden hamsters infected with YFV, the compound effectively reduces serum alanine aminotransferase levels, delays mortality, and decreases viral titers in the liver, particularly when administered at higher dosages. However, it shows limited efficacy in inhibiting cytopathic effects in African green monkey Vero cells infected with YFV, with EC50 values ranging from 1,080,000 nM to 2,630,000 nM, and has a Selectivity Index above 3.6.
Against Influenza virus strains in MDCK cells, β-Anomer significantly reduces viral replication, demonstrating higher potency against the Influenza B strain with EC50 values between 19,000 nM and 24,000 nM. The compound's cytotoxic effects are low, with CC50 values exceeding 250,000 nM.
β-Anomer does not exhibit antifungal or antibacterial activity against a variety of pathogens, including Candida albicans, Cryptococcus neoformans, and several bacterial strains such as Escherichia coli and Staphylococcus aureus. It also does not cause hemolysis of human red blood cells, and it shows low cytotoxicity against HEK293 cells.
Overall, β-Anomer shows promise as an antiviral agent, particularly in animal models, but further studies are needed to fully understand its efficacy and safety profiles..
Note: Summary generated by AI. Data source: ChEMBL 